Spark los­es an­oth­er top ex­ec in the wake of $4.3B takeover by Roche — re­port

Days af­ter bid­ding farewell to co-founder Kathy High, Spark Ther­a­peu­tics — now op­er­at­ing un­der Roche — has one more open­ing on its C-suite.

Kathy Reape

Kathy Reape, who joined the Philadel­phia-based biotech in 2016 as head of clin­i­cal R&D and be­came chief med­ical of­fi­cer in 2018, is re­port­ed­ly set to leave.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER